Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash & Equivalents (2016 - 2026)

Ani Pharmaceuticals' Cash & Equivalents history spans 16 years, with the latest figure at $285.6 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 97.14% to $285.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $285.6 million, a 97.14% increase, with the full-year FY2025 number at $285.6 million, up 97.14% from a year prior.
  • Cash & Equivalents hit $285.6 million in Q4 2025 for Ani Pharmaceuticals, up from $262.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for ANIP hit a ceiling of $285.6 million in Q4 2025 and a floor of $15.3 million in Q3 2021.
  • Historically, Cash & Equivalents has averaged $136.4 million across 5 years, with a median of $144.9 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: soared 1175.43% in 2021 and later plummeted 51.92% in 2022.
  • Tracing ANIP's Cash & Equivalents over 5 years: stood at $100.3 million in 2021, then crashed by 51.92% to $48.2 million in 2022, then skyrocketed by 358.49% to $221.1 million in 2023, then plummeted by 34.49% to $144.9 million in 2024, then skyrocketed by 97.14% to $285.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for ANIP at $285.6 million in Q4 2025, $262.6 million in Q3 2025, and $217.8 million in Q2 2025.